RWJ 63556 is an orally active COX-2 selective/5-lipoxygenase inhibitor with anti-inflammatory activity; it significantly inhibits the development of substance P (SP)-induced oedema in vivo and potently inhibits leukocyte influx over a 24-hour period while maintaining its in vitro eicosanoid profile.